The ROE as of September 2024 (TTM) for Karyopharm Therapeutics Inc. (KPTI) is 66.89%

According to Karyopharm Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 66.89%. This represents a change of 286.66% compared to the average of 17.30% of the last 4 quarters.

Karyopharm Therapeutics Inc. (KPTI) Historical ROE (quarterly & annually)

How has KPTI ROE performed in the past?

The mean historical ROE of Karyopharm Therapeutics Inc. over the last ten years is 10.31%. The current 66.89% ROE has changed 548.76% with respect to the historical average. Over the past ten years (40 quarters), KPTI's ROE was at its highest in in the December 2022 quarter at 231.18%. The ROE was at its lowest in in the December 2019 quarter at -97.74%.

Karyopharm Therapeutics Inc. (KPTI) ROE by Quarter and Year

Discovering the peaks and valleys of Karyopharm Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Karyopharm Therapeutics Inc. (KPTI) Average ROE

How has KPTI ROE performed in the past?

The current ROE of Karyopharm Therapeutics Inc. (KPTI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Karyopharm Therapeutics Inc. (KPTI) ROE vs. Peers

How is KPTI’s ROE compared to its peers?

Karyopharm Therapeutics Inc.’s ROE is less than X4 Pharmaceuticals, Inc. (32.93%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Mereo BioPharma Group plc (-63.39%), less than Galera Therapeutics, Inc. (21.95%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Nuvation Bio Inc. (-98.79%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than bluebird bio, Inc. (-38.30%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than PMV Pharmaceuticals, Inc. (0%), greater than Rallybio Corporation (-21.96%), greater than Generation Bio Co. (-74.08%), greater than Mersana Therapeutics, Inc. (-92.86%), greater than Monte Rosa Therapeutics, Inc. (-333.91%), greater than null (-70.40%),

Build a custom stock screener for Karyopharm Therapeutics Inc. (KPTI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Karyopharm Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Karyopharm Therapeutics Inc. (KPTI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Karyopharm Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.